ADC Therapeutics (ADCT) Price & Analysis

Compare

402 Followers

ADCT Stock Chart & Stats

$3.67

-$0.05(-2.50%)

At close: Jan 08 4:00 PM EST

$3.67

-$0.05(-2.50%)

Day’s Range― - ―

52-Week Range$1.05 - $4.80

Previous CloseN/A

Volume185.04K

Average Volume (3M)1.26M

Market Cap

$491.79M

Enterprise Value$768.48M

Total Cash (Recent Filing)$234.74M

Total Debt (Recent Filing)$117.27M

Price to Earnings (P/E)―

Beta2.16

Next Earnings

Mar 12, 2026

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding123,877,110

10 Day Avg. Volume2,177,579

30 Day Avg. Volume1,256,694

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)-0.95

Price to Sales (P/S)2.73

P/FCF Ratio-1.55

Enterprise Value/Market Cap1.56

Enterprise Value/Revenue10.22

Enterprise Value/Gross Profit11.02

Enterprise Value/Ebitda-6.77

Forecast

1Y Price Target

$7.33

Price Target Upside99.73% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-1.44

Revenue Forecast (FY)$76.65M

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe LOTIS-7 trial results for ZYNLONTA in combination with glofitamab show an 89.8% overall response rate, which is significantly better than the majority of competitor regimens in the 2L DLBCL space.

Financial PerformanceADC Therapeutics recorded a net loss of $0.30 per share—narrower than our previously estimated net loss of $0.40 per share.

Regulatory Approval ProspectsManagement guides to a potential confirmatory approval from the FDA in 2L+ DLBCL based on the LOTIS-5 results.

Bears Say

Approval And Market RisksRisks include inability to obtain timely approval for ADCT-402 in DLBCL and slower than anticipated market uptake for ADCT-402.

Market CompetitionThe evolving treatment landscape could affect the uptake of ZYNLONTA + glofitamab as new competitors emerge in the market.

Price Target AdjustmentThe 12-month price target for ADC Therapeutics has been slightly lowered to $7 per share from the previous $8 per share.

ADC Therapeutics News

ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma

ADC Therapeutics (ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and...

16d ago

ADCT

ADC Therapeutics Reports Promising LOTIS-7 Trial Results

ADC Therapeutics ( ($ADCT) ) has provided an announcement. On December 3, 2025, ADC Therapeutics announced updated results...

14d ago

ADCT

Promising LOTIS-7 Trial Results Reinforce Buy Rating for ADC Therapeutics

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on ADC Therapeutics. The associated price target...

16d ago

ADCT

ADC Therapeutics: Strong Financials and Upcoming Trial Catalysts Support Buy Rating

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on ADC Therapeutics. The associated price target...

1M ago

ADCT

ADC Therapeutics Reports Q3 2025 Financial Results

ADC Therapeutics Ltd ( ($ADCT) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

ADCT

ADC Therapeutics Q3 2025 Earnings Call Highlights

ADC Therapeutics Ltd (($ADCT)) has held its Q3 earnings call. Read on for the main highlights of the...

1M ago

ADCT

ADC Therapeutics files to sell 14.7M common shares for holders

17:25 EST ADC Therapeutics (ADCT) files to sell 14.7M common shares for holders Published first on TheFly –...

1M ago

ADCT

ADC Therapeutics reports Q3 adjsuted EPS (19c), consensus (36c)

Reports Q3 revenue $15.8M, consensus $16.79M. As of September 30 cash and cash equivalents were $234.7M, compared to...

1M ago

ADCT

Is ADCT a Buy, Before Earnings?

ADC Therapeutics Ltd (ADCT) is scheduled to report 3rd quarter earnings on 11/10/2025, before the market opens. Regarding...

1M ago

ADCT

ADC Therapeutics’ LOTIS-7 Study: A Promising Update for Investors

ADC Therapeutics Ltd (($ADCT)) announced an update on their ongoing clinical study. ADC Therapeutics Ltd is conducting a...

2M ago

ADCT

ADC Therapeutics’ LOTIS-10 Study: A Step Forward in Lymphoma Treatment

ADC Therapeutics Ltd (($ADCT)) announced an update on their ongoing clinical study. ADC Therapeutics Ltd is conducting a...

2M ago

ADCT

ADC Therapeutics price target lowered to $7 from $8 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on ADC Therapeutics (ADCT) to $7 from $8...

2M ago

ADCT

ADC Therapeutics Announces $60M Private Placement

ADC Therapeutics ( ($ADCT) ) has issued an announcement. On October 12, 2025, ADC Therapeutics announced a $60...

2M ago

ADCT

ADC Therapeutics sees Q3 sales of zynlonta about $15.8M

The company expects net product revenues from sales of zynlonta to be approximately $15.8M for the third quarter...

2M ago

ADCT

ADCT FAQ

What was ADC Therapeutics Ltd’s price range in the past 12 months?

ADC Therapeutics Ltd lowest stock price was $1.05 and its highest was $4.80 in the past 12 months.

What is ADC Therapeutics Ltd’s market cap?

ADC Therapeutics Ltd’s market cap is $491.79M.

When is ADC Therapeutics Ltd’s upcoming earnings report date?

ADC Therapeutics Ltd’s upcoming earnings report date is Mar 12, 2026 which is in 83 days.

How were ADC Therapeutics Ltd’s earnings last quarter?

ADC Therapeutics Ltd released its earnings results on Nov 10, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.363 by $0.063.

Is ADC Therapeutics Ltd overvalued?

According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ADC Therapeutics Ltd pay dividends?

ADC Therapeutics Ltd does not currently pay dividends.

What is ADC Therapeutics Ltd’s EPS estimate?

ADC Therapeutics Ltd’s EPS estimate is -0.29.

How many shares outstanding does ADC Therapeutics Ltd have?

ADC Therapeutics Ltd has 123,877,110 shares outstanding.

What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?

ADC Therapeutics Ltd reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.363. Following the earnings report the stock price went up 4.208%.

Which hedge fund is a major shareholder of ADC Therapeutics Ltd?

Currently, no hedge funds are holding shares in ADCT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

ADC Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-16.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ADC Therapeutics Ltd

ADC Therapeutics (ADCT) is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company leverages its proprietary technology platform to create targeted therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, aiming to improve efficacy and reduce side effects compared to traditional cancer treatments. ADCT's pipeline includes several clinical-stage candidates, with a focus on innovative therapies designed to address unmet medical needs in oncology.

ADC Therapeutics (ADCT) Earnings & Revenues

Historic Earnings Reports

ADCT Company Deck

ADCT Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted stable revenues, promising clinical trial results, and a strong financial position, offset by a decline in year-over-year revenues and ongoing net loss.View all ADCT earnings summaries

ADCT Stock 12 Month Forecast

Average Price Target

$7.33

▲(99.73% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.24,4.683076923076923,5.126153846153846,5.569230769230769,6.012307692307692,6.455384615384615,6.898461538461539,7.341538461538462,7.7846153846153845,8.227692307692308,8.670769230769231,9.113846153846154,9.556923076923077,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.24,4.477692307692308,4.7153846153846155,4.953076923076924,5.190769230769231,5.428461538461539,5.666153846153846,5.903846153846154,6.141538461538461,6.3792307692307695,6.616923076923078,6.854615384615385,7.092307692307692,{"y":7.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.24,4.298461538461539,4.356923076923077,4.415384615384616,4.473846153846154,4.532307692307692,4.590769230769231,4.649230769230769,4.707692307692308,4.766153846153847,4.8246153846153845,4.883076923076923,4.941538461538461,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >